Can a targeted drug shrink rare salivary gland tumors?

NCT ID NCT04119453

Terminated Disease control Sponsor: Elevar Therapeutics Source: ClinicalTrials.gov ↗

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This phase 2 trial is testing the drug rivoceranib in adults with recurrent or metastatic adenoid cystic carcinoma, a rare cancer that often starts in the salivary glands. The study aims to see if the drug can shrink tumors or slow the disease. Participants take rivoceranib tablets and are monitored for response and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a drug called rivoceranib (also known as apatinib)
What this could lead to: If it works, this could offer a new treatment option for people with recurrent or metastatic adenoid cystic carcinoma, a rare cancer with few approved therapies.
What could go wrong: This is a phase 2 trial, so the drug is still being tested for safety and effectiveness. It may not shrink tumors or improve survival, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenoid cystic carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADENOID CYSTIC CARCINOMA

Contacts and locations

Locations

Asan Medical Center

Seoul, Gyeonggi-do, South Korea
Dana-Farber Cancer Institute - Head and Neck Oncology

Boston, Massachusetts, 02215, United States
H. Lee Moffitt Cancer Center & Research Institute

Tampa, Florida, 33612, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
National Cancer Center

Goyang-si, Gyeonggi-do, South Korea
Samsung Medical Center

Seoul, South Korea
Seoul National University Hospital

Seoul, Gyeonggi-do, South Korea
UCSF

San Francisco, California, 94143, United States
University of California, Los Angeles (UCLA)

Los Angeles, California, 90095, United States
University of Colorado Denver

Denver, Colorado, 80204, United States
University of Michigan

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.